Akebia Therapeutics Inc

詳細情報 Akebia Therapeutics Inc 企業名

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

企業情報

企業コードAKBA

会社名Akebia Therapeutics Inc

上場日Mar 20, 2014

最高経営責任者「CEO」Mr. John P. Butler

従業員数181

証券種類Ordinary Share

決算期末Mar 20

本社所在地245 First Street

都市CAMBRIDGE

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号02142

電話番号16178712098

ウェブサイトhttps://akebia.com/

企業コードAKBA

上場日Mar 20, 2014

最高経営責任者「CEO」Mr. John P. Butler

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Ms. Leanne M. Zumwalt

Independent Director

79.40K

+81.69%

Mr. Nicholas (Nik) Grund

Senior Vice President, Chief Commercial Officer

45.48K

-89.72%

Mr. Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer

--

-100.00%

Dr. Steven K. Burke, M.D.

Senior Vice President - Research and Development, Chief Medical Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

6.25%

The Vanguard Group, Inc.

5.51%

State Street Global Advisors (US)

3.02%

Geode Capital Management, L.L.C.

2.29%

Alerce Investment Management, L.P.

2.17%

他の

80.76%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

6.25%

The Vanguard Group, Inc.

5.51%

State Street Global Advisors (US)

3.02%

Geode Capital Management, L.L.C.

2.29%

Alerce Investment Management, L.P.

2.17%

他の

80.76%

種類

株主統計

比率

Investment Advisor

16.68%

Investment Advisor/Hedge Fund

13.06%

Hedge Fund

7.04%

Research Firm

3.98%

Individual Investor

3.57%

Private Equity

2.17%

Bank and Trust

0.18%

Pension Fund

0.11%

Venture Capital

0.06%

他の

53.17%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

284

112.41M

42.78%

+33.09M

2025Q1

280

111.54M

42.50%

+30.68M

2024Q4

258

78.54M

36.08%

+7.41M

2024Q3

257

64.16M

30.51%

-2.18M

2024Q2

248

61.31M

29.27%

-7.52M

2024Q1

290

61.37M

29.36%

-12.30M

2023Q4

289

58.79M

31.24%

-20.79M

2023Q3

300

57.28M

30.45%

-25.18M

2023Q2

308

56.18M

30.22%

-26.52M

2023Q1

315

56.14M

30.23%

-26.40M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

13.97M

5.32%

+133.23K

+0.96%

Mar 31, 2025

The Vanguard Group, Inc.

12.69M

4.83%

+1.80M

+16.55%

Mar 31, 2025

State Street Global Advisors (US)

6.81M

2.59%

+501.11K

+7.95%

Mar 31, 2025

Geode Capital Management, L.L.C.

5.03M

1.92%

+235.65K

+4.91%

Mar 31, 2025

Alerce Investment Management, L.P.

5.75M

2.19%

--

Dec 31, 2024

Satter Muneer A

5.75M

2.19%

+5.75M

--

Dec 31, 2024

Morgan Stanley & Co. LLC

2.09M

0.79%

+629.05K

+43.20%

Mar 31, 2025

Renaissance Technologies LLC

4.01M

1.53%

+182.30K

+4.77%

Mar 31, 2025

Goldman Sachs & Company, Inc.

2.45M

0.93%

+1.52M

+163.57%

Mar 31, 2025

詳細を見る

2.960USD

Akebia Therapeutics Inc

2.960

概要

企業名

金融

分析